Skip to content

Telomir Pharmaceuticals, Inc.: 10-Q filed 2026-05-14

What Telomir Pharmaceuticals, Inc. reported in its quarterly report filed 2026-05-14 (fiscal Q1 2026): 22 published measures, 44 facts as tagged in accession 0001493152-26-023010.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-14
Fiscal period
fiscal Q1 2026
Accession
0001493152-26-023010 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Telomir Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-315,789,536USD
At 2025-12-317,341,361USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-31827,310USD
At 2025-12-311,427,991USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-314,962,226USD
At 2025-12-315,913,370USD
At 2025-03-31-161,105USD
At 2024-12-31643,037USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-990,947USD90
2025-01-01 to 2025-03-31-2,179,828USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1,773,510USD90
2025-01-01 to 2025-03-31-863,132USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-03-3147,351USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-42,001,010USD
At 2025-12-31-41,010,063USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-3134,380,971shares90
2025-01-01 to 2025-03-3129,762,671shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-3134,380,971shares90
2025-01-01 to 2025-03-3129,762,671shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.03USD/shares90
2025-01-01 to 2025-03-31-0.07USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.03USD/shares90
2025-01-01 to 2025-03-31-0.07USD/shares90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-03-3139,803USD90
2025-01-01 to 2025-03-311,375,686USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-315,789,536USD
At 2025-12-317,341,361USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-31827,310USD
At 2025-12-311,427,991USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,041,336USD90
2025-01-01 to 2025-03-312,187,782USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-31467,797USD90
2025-01-01 to 2025-03-31336,996USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-3134,380,971shares
At 2025-12-3134,380,971shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-3146,963,236USD
At 2025-12-3146,923,433USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31573,539USD90
2025-01-01 to 2025-03-311,850,786USD90

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,255USD90
2025-01-01 to 2025-03-3146USD90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-01-01 to 2026-03-3150,389USD90
2025-01-01 to 2025-03-317,954USD90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,255USD90

Inspect the source

Entity
Telomir Pharmaceuticals, Inc. / CIK 0001971532
Captured
2026-09-21T17:36:59.180Z
SEC response SHA-256
2bf53a6ee4392d72c55462c84b1ae1101543d1b4cd3306c9906ab52eae14a73f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001971532.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))